Navigation Links
Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
Date:10/2/2009

Dr. Brad Thompson, President and CEO of Oncolytics, will host a conference call and webcast today, October 2, 2009 at 6:30 a.m. MT (8:30 a.m. ET) to update investors on the Phase 3 program for REOLYSIN. To access the conference call by telephone, dial 1-416-644-3426 or 1-800-732-1073. A live audio webcast will also be available at the following link: http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2828320 or through the Company's website at www.oncolyticsbiotech.com. Please connect at least 15 minutes prior to the webcast to ensure adequate time for any software download that may be needed. A replay of the webcast will be available at www.oncolyticsbiotech.com and will also be available by telephone through October 9, 2009. To access the telephone replay, dial 1-416-640-1917 or 1-877-289-8525 and enter reservation number 4169017 followed by the number sign.

About the Special Protocol Assessment Process

Upon the request of a study sponsor, the FDA will evaluate certain protocols and issues relating to the protocols to assess whether they are adequate to meet scientific and regulatory requirements; this includes clinical protocols for Phase 3 trials whose data will form the primary basis for an efficacy claim that will be part of an original Biologics License Application. For more information about the SPA process, please go to:

http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm080571.pdf

About REOLYSIN

REOLYSIN is a proprietary formulation of the human reovirus that acts primarily as a direct cytotoxic agent. Reovirus is naturally occurring (not genetically engineered) and has been
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... , October 27, 2014 Investor-Edge ... Inc. (NASDAQ: NBIX ), Insmed Inc. (NASDAQ: ... BCRX ), Dyax Corporation (NASDAQ: DYAX ... these five companies can be accessed at: http://investor-edge.com/register ... NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow ...
(Date:10/26/2014)... The report "Protective Coatings Market by ... Trends & Forecast to 2019", defines and segments the ... volume consumed and value generated. The protective coatings consumption ... to 6,701.3 KT by 2019, at a CAGR of ... data tables and 22 figures spread through 219 slides ...
(Date:10/25/2014)... Angeles, California (PRWEB) October 23, 2014 ... ), a specialty pharmaceutical company devoted to bringing ... out-licensing partnerships in 2015. , ViaDerma has developed ... which allows for rapid mass transfer of pharmaceutical ... the body to provide immediate localized therapy. The ...
(Date:10/25/2014)... According to new market research report "Data ... Enterprise, Telecom), by Design Types (Electrical, Mechanical), and ... 3, Tier 4) - Global Forecast to 2019", ... Center Construction Market into various segments with an ... report also identifies the factors driving this market, ...
Breaking Biology Technology:Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 2Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 3Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 4ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4
... CAMBRIDGE, Mass., Nov. 18 Knome, Inc., a ... announced the launch of KnomeDISCOVERY, the first fully ... for researchers. The new offering meets rapidly emerging ... that bundles affordable, research-tailored access to a broad ...
... LONDON, November 18 , - ... - An Estimated Two Billion Work Hours Lost Each Week , ... first time that,people between the ages of 40 to 65 are emerging as ... experts, the,report uncovers a new, younger majority of COPD patients(1) who are in ...
... ... Sonitor,s Ultrasound identification (USID) technology is now including Wi-Fi to enable the ultimate hospital ... , ... November 18, 2009 -- One of the many advantages of Sonitor,s recently released High ...
Cached Biology Technology:Knome Launches First Platform-Agnostic Human Genome Sequencing and Analysis Service for Researchers 2Knome Launches First Platform-Agnostic Human Genome Sequencing and Analysis Service for Researchers 3Mainstay of the Global Workforce - 40-65 Year Olds - Hit Hardest by Chronic Obstructive Pulmonary Disease (COPD) 2Mainstay of the Global Workforce - 40-65 Year Olds - Hit Hardest by Chronic Obstructive Pulmonary Disease (COPD) 3Mainstay of the Global Workforce - 40-65 Year Olds - Hit Hardest by Chronic Obstructive Pulmonary Disease (COPD) 4Hand-washing Compliance, Computer Auto Log-on/ Log-off and Patient Fall-detection are Enabled by Real Time Location System (RTLS) with Sub-room Location Accuracy 2Hand-washing Compliance, Computer Auto Log-on/ Log-off and Patient Fall-detection are Enabled by Real Time Location System (RTLS) with Sub-room Location Accuracy 3Hand-washing Compliance, Computer Auto Log-on/ Log-off and Patient Fall-detection are Enabled by Real Time Location System (RTLS) with Sub-room Location Accuracy 4
(Date:10/30/2014)... 30 October 2014 Biological membranes are mainly composed ... adsorption of solution ions onto lipid membranes helps ... new study provides a quantitative description of the ... Joanna Kotyńska and Zbigniew Figaszewski from the University ... study describing these findings, just published in ...
(Date:10/29/2014)... their hair as a consequence of chemotherapy will benefit ... scalp cooling technology that prevents hair loss. , The ... by global scalp cooling manufacturing company, Paxman Coolers, of ... of the University of Huddersfield. , The research will ... a background in the pharmacology of cancer treatment, which ...
(Date:10/29/2014)... Online registration is open for the ... Scientific Meeting. SIR 2015 is the one ... trainees and related health care professionals can ... image-guided science and technologies being presented, discussed ... community in minimally invasive, image-guided medicine, SIR ...
Breaking Biology News(10 mins):Ion adsorption matter in biology 2New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2SIR 2015: Interventional radiology shapes tomorrow's medicine 2
... is the life-blood of agriculture; it is the liquid elixir ... needed to feed the world. The ample supply of water ... and famine. Many parts of the world, however, suffer from ... agriculture. The reasons can range from drought and desertification to ...
... of experts from the Society for Healthcare Epidemiology (SHEA) ... released online new clinical practice guidelines for Clostridium ... to be published in the May issue of ... the epidemiology, diagnosis, treatment and infection control and environmental ...
... The brains of males and females, and how they use ... least in the fruit fly Drosophila melanogaster , according ... paper published today in the journal Nature Neuroscience , ... Oxford, have shown that the gene known as ,doublesex, (dsx), ...
Cached Biology News:More water for life 2More water for life 3New guidelines for diagnosing, managing and treating Clostridium difficile 2Sex on the brain: 'Doublesex' gene key to determining fruit fly gender 2Sex on the brain: 'Doublesex' gene key to determining fruit fly gender 3
Request Info...
Multidrop Micro high speed 1 l bulk reagent dispenser rapidly, precisely and accurately dispenses microvolumes of 1-50 l into 384- and 96-well microplates....
...
...
Biology Products: